Literature DB >> 28419274

Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies.

Christian M Madsen1,2,3, Anette Varbo1,2,3, Børge G Nordestgaard1,2,3,4.   

Abstract

AIMS: High-density lipoprotein (HDL) cholesterol concentrations are inversely associated with cardiovascular disease and mortality across a range of concentrations, but genetic evidence suggest that extreme high concentrations may paradoxically lead to more cardiovascular disease. We tested the hypothesis that extreme high concentrations of HDL cholesterol are associated with high all-cause mortality in men and women. METHODS AND
RESULTS: A total of 52 268 men and 64 240 women were included from the two prospective population-based studies, the Copenhagen City Heart Study and the Copenhagen General Population Study. During 745 452 person-years of follow-up, number of deaths from any cause were 5619 (mortality rate, 17.1/1000 person-years (95% confidence interval (CI): 16.7-17.6)) in men and 5059 (mortality rate, 12.1/1000 person-years (11.8-12.4)) in women. The association between HDL cholesterol concentrations and all-cause mortality was U-shaped for both men and women, with both extreme high and low concentrations being associated with high all-cause mortality risk. The concentration of HDL cholesterol associated with the lowest all-cause mortality was 1.9 mmol/L (95% CI: 1.4-2.0) (73 mg/dL (54-77)) in men and 2.4 mmol/L (1.8-2.5) (93 mg/dL (69-97)) in women. When compared with the groups with the lowest risk, the multifactorially adjusted hazard ratios for all-cause mortality were 1.36 (95% CI: 1.09-1.70) for men with HDL cholesterol of 2.5-2.99 mmol/L (97-115 mg/dL) and 2.06 (1.44-2.95) for men with HDL cholesterol ≥3.0 mmol/L (116 mg/dL). For women, corresponding hazard ratios were 1.10 (0.83-1.46) for HDL cholesterol of 3.0-3.49 mmol/L (116-134 mg/dL) and 1.68 (1.09-2.58) for HDL cholesterol ≥3.5 mmol/L (135 mg/dL).
CONCLUSION: Men and women in the general population with extreme high HDL cholesterol paradoxically have high all-cause mortality. These findings need confirmation in other studies. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Epidemiology; General population; HDL; Lipids; Lipoproteins; Mortality

Mesh:

Substances:

Year:  2017        PMID: 28419274     DOI: 10.1093/eurheartj/ehx163

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  128 in total

1.  Inverse Association Between HDL (High-Density Lipoprotein) Cholesterol and Stroke Risk Among Patients With Type 2 Diabetes Mellitus.

Authors:  Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Alessandra N Bazzano; Somesh Nigam; Gang Hu
Journal:  Stroke       Date:  2019-02       Impact factor: 7.914

Review 2.  Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.

Authors:  José Tuñón; Lina Badimón; Marie-Luce Bochaton-Piallat; Bertrand Cariou; Mat J Daemen; Jesus Egido; Paul C Evans; Imo E Hoefer; Daniel F J Ketelhuth; Esther Lutgens; Christian M Matter; Claudia Monaco; Sabine Steffens; Erik Stroes; Cécile Vindis; Christian Weber; Magnus Bäck
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

3.  A novel healthy metabolic phenotype developed among a cohort of families enriched for longevity.

Authors:  Megan M Marron; Iva Miljkovic; Robert M Boudreau; Kaare Christensen; Mary F Feitosa; Joseph H Lee; Paola Sebastiani; Bharat Thyagarajan; Mary K Wojczynski; Joseph M Zmuda; Anne B Newman
Journal:  Metabolism       Date:  2019-01-30       Impact factor: 8.694

4.  Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients.

Authors:  Yasunori Suematsu; Masaki Goto; Christina Park; Ane C F Nunes; WangHui Jing; Elani Streja; Connie M Rhee; Siobanth Cruz; Moti L Kashyap; Nosratola D Vaziri; Vasanthy Narayanaswami; Kamyar Kalantar-Zadeh; Hamid Moradi
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

5.  A big data approach to examine the association of high density lipoprotein cholesterol and mortality: lessons for future investigations.

Authors:  Ziyad Al-Aly
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

6.  A new method for measuring cholesterol efflux capacity uses stable isotope-labeled, not radioactive-labeled, cholesterol.

Authors:  Tomo Shimizu; Osamu Miyazaki; Takeo Iwamoto; Tomoyuki Usui; Ryo Sato; Chika Hiraishi; Hiroshi Yoshida
Journal:  J Lipid Res       Date:  2019-08-27       Impact factor: 5.922

Review 7.  [Inborn errors of high-density lipoprotein metabolism].

Authors:  Arnold von Eckardstein
Journal:  Internist (Berl)       Date:  2019-12       Impact factor: 0.743

Review 8.  HDL therapy today: from atherosclerosis, to stent compatibility to heart failure.

Authors:  C R Sirtori; M Ruscica; L Calabresi; G Chiesa; R Giovannoni; J J Badimon
Journal:  Ann Med       Date:  2019 Nov - Dec       Impact factor: 4.709

9.  Longitudinal lipid trends and adverse outcomes in patients with CKD: a 13-year observational cohort study.

Authors:  Ching-Wei Tsai; Han-Chun Huang; Hsiu-Yin Chiang; Chih-Wei Chung; Shih-Ni Chang; Pei-Lun Chu; Chin-Chi Kuo
Journal:  J Lipid Res       Date:  2019-01-14       Impact factor: 5.922

Review 10.  Deepening our understanding of HDL proteome.

Authors:  Graziella Eliza Ronsein; Tomáš Vaisar
Journal:  Expert Rev Proteomics       Date:  2019-08-27       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.